{"organizations": [], "uuid": "007366bab8bb26162ace5f36825f06da7e763bbc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-akcea-initiates-phase-2b-study-of/brief-akcea-initiates-phase-2b-study-of-hypertriglyceridemia-and-established-heart-disease-treatment-idUSFWN1P010Q", "country": "US", "domain_rank": 408, "title": "BRIEF-Akcea Initiates Phase 2b Study Of Hypertriglyceridemia And Established Heart Disease Treatment", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-05T23:24:00.000+02:00", "replies_count": 0, "uuid": "007366bab8bb26162ace5f36825f06da7e763bbc"}, "author": "", "url": "https://www.reuters.com/article/brief-akcea-initiates-phase-2b-study-of/brief-akcea-initiates-phase-2b-study-of-hypertriglyceridemia-and-established-heart-disease-treatment-idUSFWN1P010Q", "ord_in_thread": 0, "title": "BRIEF-Akcea Initiates Phase 2b Study Of Hypertriglyceridemia And Established Heart Disease Treatment", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "akcea therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 25 PM / in 9 minutes BRIEF-Akcea Initiates Phase 2b Study Of Hypertriglyceridemia And Established Heart Disease Treatment Reuters Staff \nJan 5 (Reuters) - Akcea Therapeutics Inc: \n* AKCEA INITIATES PHASE 2B STUDY OF AKCEA-APOCIII-LRX IN PATIENTS WITH HYPERTRIGLYCERIDEMIA AND ESTABLISHED CARDIOVASCULAR DISEASE \n* AKCEA THERAPEUTICS INC - ‍ ANTICIPATES REPORTING TOP-LINE DATA FROM PHASE 2B OF AKCEA-APOCIII-L(RX)​ STUDY IN 2019 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-05T23:24:00.000+02:00", "crawled": "2018-01-05T23:36:27.016+02:00", "highlightTitle": ""}